We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Cambridge Cognition Holdings Plc | LSE:COG | London | Ordinary Share | GB00B8DV9647 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 52.00 | 51.00 | 53.00 | 52.00 | 52.00 | 52.00 | 30,351 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 12.61M | -409k | -0.0117 | -44.44 | 18.12M |
From Apr 2019 to Apr 2024
TIDMCOG
RNS Number : 1878X
Cambridge Cognition Holdings PLC
20 February 2017
20 February 2017
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')
Appointment of Joint Broker
The neuroscience digital health company Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG) announces that Dowgate Capital Stockbrokers Limited has been appointed as Joint Broker to the Company, with immediate effect. finnCap Ltd remains the Company's Nominated Adviser and Joint Broker.
Enquiries
Hot Features
Premium
Cambridge Cognition Holdings PLC
Steven Powell, Chief Executive Tel: 01223 810
Officer 700
Noah Konig, Director of Marketing press@camcog.com
and Communications
finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220
Geoff Nash / Simon Hicks 0500
Alice Lane (Corporate Finance)
(Corporate Broking)
Dowgate Capital Stockbrokers Limited Tel: 01293 517
David Poutney / James Serjeant 744
Notes to editors
About Cambridge Cognition Holdings PLC
Cambridge Cognition is a neuroscience digital health company specialising in the precise measurement of clinical outcomes in neurological disorders. The Company develops and markets validated near patient assessment products using cognition as a biomarker to improve understanding, diagnosis and treatment in brain health worldwide.
Partners include the world's leading drug development companies, academic institutions and public-private health organisations.
www.cambridgecognition.com @CANTABconnect press@camcog.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
APPGCGDDBUBBGRR
(END) Dow Jones Newswires
February 20, 2017 02:01 ET (07:01 GMT)
1 Year Cambridge Cognition Chart |
1 Month Cambridge Cognition Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
